Evidence 360 Summit
Real-World Evidence, Market Access & HEOR
“Turning Evidence Into Value. Turning Value Into Patient Access.”
Bringing together senior leaders across real-world evidence, market access, HEOR, US payers, and pricing to explore evidence generation, regulatory integration, and value demonstration across the healthcare ecosystem.
Event Overview
Getting an innovative medicine to market is only one part of the journey. Ensuring that it receives appropriate coverage, demonstrates value to healthcare decision-makers, and reaches the patients who need it presents a different set of challenges.
The 3rd Annual EVIDENCE 360 Summit – USA Edition, hosted by Veridon Global, will bring together pharmaceutical and biotechnology leaders, market access specialists, HEOR professionals, RWE experts, payer representatives, and industry solution providers for two days of focused discussion on the changing US healthcare landscape.
The summit will explore the commercial and scientific considerations influencing how medicines are priced, evaluated, reimbursed, and accessed.
From negotiating with commercial payers and navigating PBM relationships to understanding Medicare policy changes, developing compelling health economic models, and generating meaningful real-world evidence, the programme will address the issues that matter across the product lifecycle.
Particular attention will be given to the growing need to connect clinical outcomes with economic value, understand different payer requirements, and build evidence strategies that can withstand scrutiny from multiple healthcare stakeholders.
Through industry-led presentations, practical case studies, expert panels, and interactive discussions, EVIDENCE 360 will provide a dedicated setting to exchange experiences, challenge existing approaches, and explore more effective ways of advancing market access and patient outcomes in the United States.
Send an Enquiry
Have questions about participating or need the full summit brochure?
Evidence 360 Summit at a Glance
Makers
Key Discussion Areas for 2027
Addressing critical commercial, economic, and scientific priorities across the US healthcare and payer landscape.
The Changing US Market Access Environment
How evolving healthcare policies, payer expectations, and commercial pressures are influencing pharmaceutical market access strategies.
PBM Relationships & Formulary Positioning
Understanding the commercial considerations behind formulary decisions, rebate structures, coverage restrictions, and payer negotiations.
Medicare Drug Price Negotiation & IRA Implications
Examining how Medicare drug price negotiation and wider affordability developments influence pharmaceutical pricing, portfolio planning, and market access decisions.
Pricing Strategy & Market Positioning
Building pricing approaches that reflect clinical differentiation, economic value, competition, and payer expectations.
HEOR in Commercial Decision-Making
Using health economics and outcomes research to communicate product value and strengthen market access strategies.
Cost-Effectiveness & Budget Impact
Developing economic assessments that help decision-makers understand the financial and healthcare implications of treatment choices.
RWE for Payer Engagement
Exploring how evidence from routine clinical practice can address payer questions and support coverage and reimbursement discussions.
Comparative Effectiveness & Evidence Gaps
Understanding the role of comparative evidence, indirect comparisons, and observational research in assessing treatment value.
Coverage, Reimbursement & Patient Access
Addressing practical challenges associated with prior authorisation, step therapy, specialty pharmacy pathways, and patient affordability.
Medicare & Medicaid Considerations
Examining access and reimbursement requirements across government healthcare programmes.
Regulatory Applications of RWE
Understanding the scientific and methodological considerations involved in using real-world evidence in regulatory decision-making.
Value-Based Contracting
Exploring the practicalities of outcomes-based agreements, risk-sharing arrangements, and alternative reimbursement models.
Evidence for Specialty & High-Cost Therapies
Addressing the challenges of demonstrating value for oncology, rare diseases, specialty medicines, and advanced therapies.
Patient Outcomes & Treatment Experience
Bringing patient-reported outcomes, quality of life, and treatment burden into value assessment.
AI & Data-Driven Evidence Development
Examining the potential of advanced analytics and AI to improve evidence generation, economic modelling, and healthcare insights.
Post-Launch Value & Lifecycle Strategy
Understanding how companies can continue demonstrating product value as treatment patterns, competition, and payer expectations evolve.
Why Philadelphia?
Philadelphia offers a relevant setting for a gathering focused on the US pharmaceutical and healthcare landscape.
The Greater Philadelphia region is home to a diverse life sciences community, with pharmaceutical and biotechnology companies, research institutions, academic medical centres, healthcare providers, and specialist service organisations.
Its position within the Northeast healthcare and life sciences corridor also makes it accessible to professionals across several important US markets.
For EVIDENCE 360, Philadelphia provides an opportunity to bring together professionals working across market access, pricing, HEOR, RWE, payer strategy, and evidence generation for two days of focused industry engagement.
Life Sciences Capital
Surrounded by major global pharma headquarters, biotech innovators, and top-tier academic medical institutions.
Northeast Corridor Hub
Strategically positioned with seamless rail and air transit from NYC, Boston, New Jersey, and Washington, D.C.
High-Impact Networking
A central gathering point for commercial, clinical, and payer stakeholders across the United States.
Why Attend?
Equipping leaders with actionable strategies, cross-stakeholder perspectives, and evidence models built for real-world impact.
Gain a broader understanding of the US access environment
Explore the commercial and policy developments affecting pharmaceutical manufacturers and healthcare stakeholders.
Understand the payer's perspective
Discuss what influences coverage, formulary placement, reimbursement, and contracting decisions.
Strengthen pricing and market access strategies
Explore approaches to positioning products, communicating value, and managing access barriers.
Make HEOR more commercially relevant
Understand how economic evidence can support product differentiation, payer discussions, and reimbursement strategies.
Explore practical applications of RWE
Learn how real-world data can help answer questions that clinical trials alone may not fully address.
Address affordability and reimbursement challenges
Discuss the implications of pricing pressure, government policy, and patient out-of-pocket costs.
Exchange ideas with industry peers
Meet professionals working across market access, pricing, HEOR, RWE, managed markets, and patient access in an executive networking setting.
Who Should Attend?
Bringing together cross-functional decision-makers, commercial leaders, payers, and specialized healthcare solutions providers across three core sectors.
Pharmaceutical & Biotechnology Companies
Healthcare Payers & Organisations
Solution Providers & Consulting Organisations
Who Will You Meet?
The summit will bring together professionals responsible for different aspects of the pharmaceutical value and access journey.
Commercial & Market Access Leaders
Professionals developing market access, pricing, payer engagement, and commercial strategies.
HEOR & Health Economics Specialists
Experts working on cost-effectiveness, economic modelling, budget impact, and value assessment.
RWE & Evidence Generation Professionals
Leaders responsible for real-world data, observational research, comparative effectiveness, and evidence strategy.
Payer & Managed Markets Representatives
Professionals involved in formulary decisions, coverage, reimbursement, contracting, and healthcare resource management.
Industry Solution Providers
Organisations supporting pharmaceutical companies with data, analytics, consulting, technology, and evidence development.
Why Attend EVIDENCE 360?
A focused, practical setting designed to help teams translate real-world data and economic evidence into successful commercial and reimbursement outcomes.
Gain a broader understanding of the US access environment
Explore the commercial and policy developments affecting pharmaceutical manufacturers and healthcare stakeholders.
Understand the payer's perspective
Discuss what influences coverage, formulary placement, reimbursement, and contracting decisions.
Strengthen pricing and market access strategies
Explore approaches to positioning products, communicating value, and managing access barriers.
Make HEOR more commercially relevant
Understand how economic evidence can support product differentiation, payer discussions, and reimbursement strategies.
Explore practical applications of RWE
Learn how real-world data can help answer questions that clinical trials alone may not fully address.
Address affordability and reimbursement challenges
Discuss the implications of pricing pressure, government policy, and patient out-of-pocket costs.
Exchange ideas with industry peers
Meet professionals working across market access, pricing, HEOR, RWE, managed markets, and patient access in a dedicated environment.
Featured Speakers & Panelists
The speaker faculty for the 2027 USA Edition is currently being curated and will be announced shortly.
Faculty Line-up in Development
Veridon Global is actively convening senior leaders, HEOR specialists, real-world evidence directors, and US payer representatives to lead keynote sessions, practical case presentations, and collaborative panel debates.
Agenda
MARKET ACCESS, PAYER STRATEGY, PRICING & REIMBURSEMENT
| Time | Session |
|---|---|
| 08:00 — Registration, Refreshments & Networking | |
| 08:50 | Welcome Address |
| 09:00 | Opening Remarks |
| SESSION 1: THE US MARKET ACCESS REALITY | |
| 09:10 | What Is Changing in US Pharmaceutical Market Access? |
| 09:35 | From Product Approval to Market Access: Preparing for the Commercial Journey |
| 10:00 | Industry Case Study: What Can Derail a Market Access Strategy? |
| 10:25 — Networking Break, Exhibition & 1:1 Meetings | |
| SESSION 2: MEDICARE, DRUG PRICING & POLICY DEVELOPMENTS | |
| 10:55 | Medicare Drug Price Negotiation: Strategic Implications for Manufacturers |
| 11:20 | Medicare Part B & Part D: Understanding Different Access Pathways |
| 11:45 | Medicaid & Government Pricing: Managing Access Across Public Programmes |
| 12:10 | Panel Discussion: The US Drug Pricing Environment — What Should Manufacturers Be Preparing For? |
| 12:45 — Networking Lunch, Exhibition & 1:1 Meetings | |
| SESSION 3: COMMERCIAL PAYERS, PBMs & FORMULARY STRATEGY | |
| 13:45 | Inside the Payer Decision: What Influences Formulary Placement? |
| 14:10 | PBM Strategy & Manufacturer Contracting |
| 14:35 | Managing Coverage Restrictions & Utilisation Controls |
| 15:00 | Case Study: Improving Formulary Access for a Specialty Therapy |
| 15:25 — Networking Break, Exhibition & 1:1 Meetings | |
| SESSION 4: PRICING, VALUE & MARKET POSITIONING | |
| 15:55 | Developing a Competitive Pricing Strategy for the US Market |
| 16:20 | Building a Value Proposition That Resonates With Payers |
| 16:45 | Beyond Traditional Rebates: Exploring New Contracting Approaches |
| 17:10 | Interactive Roundtable: Where Is the Biggest Gap Between Manufacturer Value Propositions and Payer Expectations? |
| 17:45 | Day 1 Closing Remarks |
HEOR, RWE, ADVANCED EVIDENCE & PATIENT OUTCOMES
| Time | Session |
|---|---|
| 08:30 — Registration, Refreshments & Networking | |
| 08:55 | Opening Remarks |
| SESSION 5: HEOR – MAKING THE CASE FOR VALUE | |
| 09:00 | How Is HEOR Influencing Pharmaceutical Market Access Decisions? |
| 09:25 | Cost-Effectiveness & Budget Impact: What Makes an Economic Case Convincing? |
| 09:50 | Comparative Effectiveness: Demonstrating Differentiation Beyond Clinical Trials |
| 10:15 — Networking Break, Exhibition & 1:1 Meetings | |
| SESSION 6: RWE – FROM DATA TO DECISION-MAKING | |
| 10:45 | Moving RWE Closer to Market Access Strategy |
| 11:10 | Claims, EHRs & Registries: Choosing the Right Data for the Right Question |
| 11:35 | Improving the Credibility of Real-World Studies |
| 12:00 | Expert Panel: What Makes RWE Persuasive Enough to Influence Coverage and Reimbursement Decisions? |
| 12:30 — Networking Lunch & Exhibition | |
| SESSION 7: REGULATORY EVIDENCE, AI & NEXT-GENERATION ANALYTICS | |
| 13:15 | FDA & Real-World Evidence: Opportunities and Practical Challenges |
| 13:35 | External Controls & Alternative Evidence Strategies |
| 13:55 | AI & Advanced Analytics: Improving the Evidence Development Process |
| 14:15 | Practical Case Study: From Fragmented Healthcare Data to Meaningful Evidence |
| SESSION 8: PATIENT OUTCOMES, VALUE-BASED CARE & POST-LAUNCH STRATEGY | |
| 14:30 | Bringing Patient Experience Into Value Assessment |
| 14:45 | Value-Based Healthcare & Post-Launch Evidence: Demonstrating Sustained Value |
| 14:55 | Closing Panel: What Will Define the Next Phase of US Market Access, HEOR & RWE? |
| 15:00 | Closing Remarks & End of Summit |
Download the full agenda to view all sessions, panel discussions, and networking slots.
Sponsor & Exhibition Opportunities
EVIDENCE 360 offers organisations working across the healthcare evidence and market access ecosystem an opportunity to engage directly with decision-makers from pharmaceutical and biotechnology companies.
Position Your Brand in Front of US Decision-Makers
The summit provides a focused platform to demonstrate expertise, introduce solutions, build senior relationships, and understand the evolving needs of the industry.
We welcome organisations interested in developing tailored partnerships aligned with their specific business objectives and target audience.
Relevant Solution Areas
Official Media & Supporting Partners
Collaborating with leading life sciences publications, healthcare journals, and industry networks to amplify insights across the global evidence and market access landscape.
Media Partners Will Be Announced Soon
The official media and publishing partners for the 3rd Annual EVIDENCE 360 Summit – USA Edition are currently being finalized and will be published shortly.
Past Sponsors & Partners
Trusted by leading pharmaceutical innovators, real-world data platforms, HEOR consultancies, and healthcare solution providers across previous editions.
Why Sponsor?
Maximize your brand influence, present groundbreaking research, and form valuable commercial partnerships with top-tier decision-makers.
Dedicated Prime Speaking Slot
Exhibition Opportunity
One-to-One Meetings
Pre-Qualified Leads
High-Level Networking
Brand Impact
Glimpses Of Our Past Edition
Highlights from high-level keynotes, interactive panel debates, and strategic networking sessions.
What Leaders Say About Evidence 360
Insights and experiences from real-world evidence directors, academic leaders, and health research pioneers.
"Well done on organising the day successfully and thanks for inviting me over. Many thanks for the photos too! I hope you can have a good break soon! I am on my way back to Bristol now."
"It was an excellent conference, good location."
"I really enjoyed the summit and I would be more than happy to present next year with findings of our research, and recommend it to fellow colleagues in cancer research and in RWE/HEOR/MA. I found the sessions useful in terms of their breadth and being able to connect with a diverse range of attendees. John Purdy was an excellent Chair, the venue team was approachable and helpful, and the refreshments provided were excellent."
Venue
Hosted in Philadelphia, Pennsylvania — an accessible life sciences hub in the heart of the US Northeast corridor.
Philadelphia, USA
Dates: 24–25 June 2027
The summit will be hosted at a premier conference venue in central Philadelphia, offering first-class facilities, dedicated exhibition halls, and executive meeting suites for all registered attendees.
Destination Highlights
Philadelphia International Airport (PHL) with non-stop domestic and transatlantic flight routes.
William H. Gray III 30th Street Station connects directly via high-speed Acela to Manhattan, Boston, and Baltimore.
Home to "Cellicon Valley" with major academic research hospitals and pharma campuses within minutes.
Contact Our Team Today
Where collaborations spark and the future of real-world evidence and market access innovation begins.
For Speaking & Partnerships
Nikita Patankar Parab
Founder, Managing Director
nikita@veridonglobal.com